Clinical Trial Update: Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a three-drug combination of estramustine, docetaxel, and carboplatin in patients with hormone-refractory prostate cancer that progresse…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Carboplatin (Paraplatin) (carboplatin)
• Docetaxel (Taxotere) (docetaxel)
• Estramustine phosphate sodium (Estracyt) (estramustine phosphate sodium)

Snippet

Sponsor: University of Southern California | Conditions: Prostate Adenocarcinoma | Phase 2 | Status: COMPLETED